Tissue Engineering Part ABioengineeringPeer-reviewed journal article
Optimizing cardiac organoid culture to enhance maturation, viability, and cardiotoxicity assessments
Anirudha Harihara, Khashayar MoshksayaniD, Nima MomtahaniD, Adela Ben‐YakariD, Janet ZoldaniD
Abstract
Development of relevant, human induced pluripotent stem cell-derived cardiac organoids is essential to recapitulate myocardium physiology and functionality for assessment of drug-induced toxicity evaluations. However, the optimal conditions for culturing self-aggregating multicellular cardiac organoids are not well-elucidated, particularly the impact of noncardiomyocytes. In this study, we generated cardiac organoids at varying seeding densities to formulate organoids that meet or exceed the biological diffusion limit. We assessed their morphology, gene expression profiles, beating functionality, viability, and mitochondrial activity over time. Our results show that organoid sizes stabilize by seven days of culture, regardless of seeding density. However, organoids seeded with 20,000 cells retained an optimal cardiac signature that promotes cardiac maturity and minimizes fibrotic tendencies, especially when culturing longer than seven days. While all organoid populations maintained their beating functionalities, those seeded with 80,000 cells exhibited greater cell shedding and increased apoptosis at long term culture. In contrast, minimal apoptosis was observed in organoids seeded with 20,000 cells after seven days. Mitochondrial staining further revealed that organoids seeded with 20,000 cells consistently demonstrated higher metabolic activity. Taken together, organoids seeded with 20,000 cells and cultured for seven days yielded the healthiest morphology, transcriptional signature, and viability, while maintaining robust beating kinetics. Importantly, compared to 2D cultures, these optimized organoids demonstrate improved sensitivity to clinically relevant doxorubicin-induced cardiotoxicity, enabling more accurate dose-response evaluations that better reflect therapeutic conditions. Impact StatementThis work highlights key tissue engineering considerations for generating self-assembling cardiac organoids suitable for scalable, high-throughput drug screening and discovery. Understanding the effect of seeding density and culture duration on organoid size and, consequently on gene expression, beating functionalities, apoptosis, and metabolic activity, has broader implications for establishing optimal organoid culture conditions. These insights enable the production of large quantities of cardiac organoids capable of modeling drug-induced toxicity effects on a clinically relevant timescale.
- organism: human
- assay: organoid / primary culture
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: clustering
- research focus: differential expression
- approach: experimental assay
- Citations
- 7
- FWCI
- 2.11
- Field percentile
- top 12%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Advanced Cardiac Organoid Model for Studying Doxorubicin-Induced Cardiotoxicity
Xian Wu, Savanna Williams, … Abdel A. Abdel‐Rahman·Toxicological SciencesPeer-reviewed·Aug 11, 2025
- Generation and Maturation of Human iPSC-derived Cardiac Organoids in Long Term Culture
E. Ergir, J. Oliver-de la Cruz, … G. Forte·bioRxiv·Mar 7, 2022
- ReCardioids: a robust human heart organoid platform to model doxorubicin- and radiotherapy-induced cardiotoxicity
Emil Rehnberg, Bjorn Baselet, … Kevin Tabury·bioRxiv·Jun 2, 2026
- Self-Assembled Chambered Cardiac Organoids for Modeling Cardiac Chamber Formation and Cardiotoxicity Assessment
Xinle Zou, Fanwen Wang, … Duanqing Pei·bioRxiv·Jul 25, 2024
- Novel 2D/3D Hybrid Organoid System for High-Throughput Drug Screening in iPSC Cardiomyocytes
Jordann Lewis, Basil Yaseen, … Anita P. Saraf·TherapeuticsPeer-reviewed·Jun 27, 2025
- Generation of human chambered cardiac organoids from pluripotent stem cells for improved modelling of cardiovascular diseases